Biodistribution study of 99mTc‐labeled LDL in B16‐melanoma‐bearing mice. Visualization of a preferential uptake by the tumor

Since there is strong evidence of a preferential LDL accumulation in tumor cells, LDL might be of interest for tumor imaging. We have tested the ability of 99mTc‐LDL in tumor imaging with B16‐melanoma‐bearing mice as a model for further applications in human studies. The LDL fixation rate was higher with 99mTc‐labeled LDL than with 125I labeled LDL. Since technetium‐99m remains trapped in the cells, 99mTc‐LDL is a well‐adapted radioligand because of information given by this radiotracer on the receptor metabolism. We observed that, at early growth stages, the tumor took up the LDL at a maximal rate, suggesting differences in cholesterol metabolism as a function of tumor growth. Accumulation of label in the tumor area was perfectly observable in tumor‐bearing mice on scintigraphic images. Computerized quantification of the regions of interest (as well as biodistribution studies including killing of the animals) showed a 1.81 ‐fold increase in uptake by the tumor as compared to the liver and a 28‐fold increase as compared with corresponding normal tissue (muscle of the left leg) at day 8 of tumor growth. These data give strong support to the value of this non‐invasive method in visualizing and quantifying the tissue LDL uptake in vivo, including the precise information provided by nuclear scintigraphy on the distribution of the radiolabeled LDL in the different tissues. 99mTc‐LDL could be an efficient tool for further diagnostic or therapeutic exploration in cancer patients.

[1]  V. P. Collins,et al.  Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. , 1990, Cancer research.

[2]  G. Schettler,et al.  Characterization of binding sites for acetylated low density lipoprotein in the rat liver in vivo and in vitro. , 1985, The EMBO journal.

[3]  G. Favre,et al.  Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro. , 1989, European journal of cancer & clinical oncology.

[4]  A. Mcfarlane,et al.  Efficient Trace-labelling of Proteins with Iodine , 1958, Nature.

[5]  E. Simpson,et al.  Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. , 1981, American journal of obstetrics and gynecology.

[6]  G. Favre,et al.  Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug--LDL complex via the LDL receptor pathway in vitro. , 1990, Biochemical pharmacology.

[7]  K. Williams,et al.  Nuclear imaging analysis of human low-density lipoprotein biodistribution in rabbits and monkeys. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  A. Fischman,et al.  Imaging Human Atherosclerosis with 99mTc‐labeled Low Density Lipoproteins , 1988, Arteriosclerosis.

[9]  S. Vitols,et al.  Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. , 1986, Cancer research.

[10]  D. Lesieur,et al.  Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells. , 1992, Cancer research.

[11]  R. Lees,et al.  Adrenal imaging with technetium-99m-labelled low density lipoproteins. , 1986, Metabolism: clinical and experimental.

[12]  V. Fuster,et al.  Radiotracers for low density lipoprotein biodistribution studies in vivo: technetium-99m low density lipoprotein versus radioiodinated low density lipoprotein preparations. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  K. Kawai,et al.  Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line. , 1987, Cancer research.

[14]  G. Canti,et al.  Assimilation of LDL by experimental tumours in mice. , 1989, Biochimica et biophysica acta.

[15]  B Lundberg,et al.  Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway. , 1987, Cancer research.

[16]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[17]  M. Brown,et al.  Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. , 1984, Journal of lipid research.

[18]  D. Bilheimer,et al.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. , 1972, Biochimica et biophysica acta.

[19]  R. Lees,et al.  Technetium-99m low density lipoproteins: preparation and biodistribution. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Brown,et al.  Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. , 1978, Blood.

[21]  V. Pirisi,et al.  New variants of B16 mouse melanoma: differentiation and metastatic properties. , 1989, Pigment cell research.

[22]  E. Simpson,et al.  Effect of cell density and confluency on cholesterol metabolism in cancer cells in monolayer culture. , 1981, Cancer research.

[23]  C. McArdle,et al.  Low-density lipoprotein metabolism in mice with soft tissue tumours. , 1984, Biochimica et biophysica acta.

[24]  M. A. Davis,et al.  A survey of reducing agents for the synthesis of tetraphenylarsonium oxotechnetiumbis(ethanedithiolate) from [99Tc] pertechnetate in aqueous solution. , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  R. Mahley,et al.  Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. , 1978, The Journal of biological chemistry.

[26]  R. Mahley,et al.  Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. , 1977, The Journal of biological chemistry.

[27]  I. Fidler,et al.  Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. , 1980, Cancer research.

[28]  External Imaging of Active Atherosclerosis with 99mTc-LDL , 1990 .

[29]  M. Brown,et al.  Atherosclerosis: the low-density lipoprotein receptor hypothesis. , 1977, Metabolism: clinical and experimental.

[30]  G. Gahrton,et al.  HYPOCHOLESTEROLAEMIA IN MALIGNANCY DUE TO ELEVATED LOW-DENSITY-LIPOPROTEIN-RECEPTOR ACTIVITY IN TUMOUR CELLS: EVIDENCE FROM STUDIES IN PATIENTS WITH LEUKAEMIA , 1985, The Lancet.

[31]  S J Goldsmith,et al.  99mTc-low density lipoprotein: intracellularly trapped radiotracer for noninvasive imaging of low density lipoprotein metabolism in vivo. , 1990, Seminars in nuclear medicine.

[32]  L. Skoog,et al.  Content of low density lipoprotein receptors in breast cancer tissue related to survival of patients. , 1986, British medical journal.

[33]  Y. Poumay,et al.  Rapid preparative isolation of concentrated low density lipoproteins and of lipoprotein-deficient serum using vertical rotor gradient ultracentrifugation. , 1985, Journal of lipid research.

[34]  S. Yanovich,et al.  Preparation and interaction of a low-density lipoprotein:daunomycin complex with P388 leukemic cells. , 1984, Cancer research.

[35]  C. Packard,et al.  Receptor-mediated low density lipoprotein catabolism in man. , 1979, Journal of lipid research.

[36]  A. Gabizon,et al.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.